Manomay Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 Cr
as on 17-11-2024
- Revenue 1027.72%
(FY 2023)
- Profit 7325.59%
(FY 2023)
- Ebitda 5246.25%
(FY 2023)
- Net Worth 1964.47%
(FY 2023)
- Total Assets 332.73%
(FY 2023)
About Manomay Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 Cr.
Anil Belkar, Saorabh Sathe, and Akash Barne serve as directors at the Company.
- CIN/LLPIN
U74999PN2018PTC177176
- Company No.
177176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Manomay Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Belkar  | Director | 13-Jun-2018 | Current |
| Saorabh Sathe | Director | 13-Jun-2018 | Current |
| Akash Barne | Director | 22-Apr-2019 | Current |
Financial Performance of Manomay Pharmaceuticals.
Manomay Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1027.72% increase. The company also saw a substantial improvement in profitability, with a 7325.59% increase in profit. The company's net worth Soared by an impressive increase of 1964.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manomay Pharmaceuticals?
In 2023, Manomay Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Regalia Pharmaceutical (India) Private LimitedActive 17 years 3 monthsAnil Belkar is a mutual person
Charges (Loans)
₹25.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Aug 2023 | Others | ₹1.00 Cr | Open |
| 19 Jul 2022 | Others | ₹1.50 Cr | Open |
How Many Employees Work at Manomay Pharmaceuticals?
Unlock and access historical data on people associated with Manomay Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manomay Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manomay Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
